Showing 401-410 of 3494 results for "".
- Staphylococcus aureus Implicated as Central Driver of Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/staphylococcus-aureus-implicated-as-central-driver-of-pediatric-atopic-dermatitis/2485614/A comprehensive literature analysis presented at the South Beach Symposium identified Staphylococcus aureus as a key contributor to pediatric atopic dermatitis (AD) pathogenesis, extending beyond disease exacerbation to underlying inflammation and prurit
- Analysis: Ustekinumab, IL-23 Inhibitors Show Higher Drug Survival in Psoriasishttps://practicaldermatology.com/news/analysis-ustekinumab-il-23-inhibitors-show-higher-drug-survival-in-psoriasis/2485295/A new Danish cohort study using data from the DERMBIO registry suggests ustekinumab was linked with the best 5-year survival of comparators in bionaive patients with psoriasis. The analysis included a total of 7,193 treatment
- NIH Grants for Vitiligo Research Rise Over Time, Driven by Medical Schools and NIAMShttps://practicaldermatology.com/news/nih-grants-for-vitiligo-research-rise-over-time-driven-by-medical-schools-and-niams/2484513/Funding trends National Institutes of Health (NIH) funding trends shows steady, long-term support for vitiligo research from 1985 through 2024, according to a new analysis. Using the NIH Research Portfolio Online Reporting To
- GLP-1 Users Drive Growth in Aesthetic Surgeryhttps://practicaldermatology.com/news/glp-1-users-drive-growth-in-aesthetic-surgery/2476140/Aesthetic surgery among patients with previous glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is increasing compared with postbariatric surgery patients, according to new research published in
- FDA Speeds Development of Hair Loss Drug Rezpegaldesleukinhttps://practicaldermatology.com/news/fda-speeds-development-of-nektars-autoimmune-hair-loss-drug/2475953/The FDA has granted Fast Track designation to the investigational biologic rezpegaldesleukin (Nektar Therapeutics) for the treatment of severe-to-very severe alopecia areata (AA) in adults and adolescents aged 12 and older who weigh at least 40 kg.
- Almirall to Present New Drug Data at EADVhttps://practicaldermatology.com/news/almirall-present-new-drug-data-eadv/2468258/Almirall will present 34 abstracts detailing the latest research on lebrikizumab for moderate-to-severe atopic dermatitis in adolescents and adults and tildrakizumab and Almirall’s CAL/BDP cream for moderate-to-severe plaque psoriasis in adults at the 33rd Congress of the European Academy of Derm
- Timber Pharmaceuticals Fails Phase 3 Trial for Congenital Ichthyosis Drug Candidatehttps://practicaldermatology.com/news/timber-pharmaceuticals-fails-phase-3-trial-congenital-ichthyosis-drug-candidate/2467911/LEO Pharma's subsidiary, Timber Pharmaceuticals, failed a late-stage trial for its investigational topical ointment formulation of isotretinoin for treating moderate to severe congenital ichthyosis. The phase 3 ASCEND trial was 12-week randomized, double-blind clinical study evaluating TM
- Emerging Technologies, Consumer Preferences Drive Microdermabrasion Market Expansionhttps://practicaldermatology.com/news/emerging-technologies-and-consumer-preferences-drive-microdermabrasion-market-expansion/2466901/A new market report indicates that microdermabrasion devices are increasingly favored in the treatment of conditions like acne, acne scars, fine lines, and wrinkles, and that the market for these devices is poised for growth. The growth, according to the report from Coherent Market Insig
- Report: Advancements and Demand To Drive Aesthetic Medicine Market to $212.5 Billion by 2032https://practicaldermatology.com/news/advancements-and-demand-drive-aesthetic-medicine-market-2125-billion-2032/2463206/A new report forecasts growth in the aesthetic medicine market. Currently valued at US$ 75.6 billion, the report says that the value of the market is projected to reach US$ 212.5 billion by 2032, reflecting a robust compound annual growth rate of 12.17% from 2024 to 2032. The report attri
- Antihypertensive Drugs Linked to Increased Eczema in Elderlyhttps://practicaldermatology.com/news/antihypertensive-drugs-linked-increased-eczema-elderly/2463140/New research suggests that increased use of antihypertensive medications is associated with an increase in eczematous dermatitis. Researchers conducted a longitudinal cohort study in a population-based sample from primary care practices in The Health Improvement Network in the United Kingd